(Reuters) -Eli Lilly’s weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration’s website showed on Wednesday.
Mounjaro has been on the FDA’s shortage list since late 2022, while Zepbound was added to the list in April this year.
The drugmaker had begun selling vials of the lowest starter dose of Zepbound in the United States through its direct-to-consumer website to help increase its availability in the marketplace.
Surging demand for Mounjaro and Zepbound has led Lilly to invest billions of dollars in boosting their production. Danish drugmaker Novo Nordisk, which makes rival drugs Ozempic and Wegovy, is also working to ramp up supply to meet unprecedented demand.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Comments